Share Based Awards (Tables)

9 Months Ended

Sep. 30, 2025

Share-Based Payment Arrangement [Abstract]

Schedule of Assumptions Used to Calculate the Fair Value of Options Granted

The range of assumptions used to calculate the fair value of options granted during the nine months ended September 30, 2025 was:

Exercise Price	$6.73 – 9.74
Stock price on date of grant	6.73 – 9.74
Risk-free interest rate	3.86 – 4.44%
Dividend yield	—
Expected term (years)	5.00 – 6.00
Volatility	135.54 – 191.15%

Schedule of Options Activity

A summary of options activity under the Plan since December 31, 2024 was:

	Shares	Weighted- Average Exercise Price		Weighted- Average Remaining Contractual Term	Aggregate Intrinsic Value
Outstanding as of December 31, 2024	5,645,325	$	1.54	7.90	$	59,779,836
Granted	1,930,850	7.50
Exercised	(2,532,848)	1.26
Forfeited or expired	(255,963)	2.16
Outstanding as of September 30, 2025	4,787,364	3.93		8.24	30,745,797
Exercisable as of September 30, 2025	1,117,144	$	1.62	5.80	$	9,756,919

Schedule of Restricted Stock Activity

A summary of restricted stock activity under the Plan since December 31, 2024 was:

	Shares	Weighted Average Grant-Date Fair Value Per Share
Unvested and outstanding as of December 31, 2024	1,544,027	$	3.84
Granted	817,242	7.03
Forfeited	(330,861)	1.06
Unvested and outstanding as of September 30, 2025	2,030,408	$	5.58

Schedule of Stock Compensation Expense by Functional Operating Expense

Stock compensation expense for the nine months ended September 30 by functional operating expense was:

	2025		2024
Research and development	$	747,363	$	338,752
Sales and marketing	2,036,318		311,164
General and administrative	4,471,739		2,391,303
Total	$	7,255,420	$	3,041,219